Regeneron (REGN) Presents Positive Data On Lymphoma Candidate
Zacks Investment Research | Jun 16, 2019 09:12PM ET
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) announced positive early-stage data for pipeline candidate, REGN1979. The data will be presented at the 24th Congress of the European Hematology Association (EHA).
REGN1979, an investigational bispecific monoclonal antibody, is being evaluated in patients with relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL). The data also includes patients with R/R diffuse large B-cell lymphoma (DLBCL), who had progressed after CAR-T therapy.
The primary objective was to assess the safety, tolerability and dose-limiting toxicities of the candidate.
High response rates observed with REGN1979 in both relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma were encouraging.
Moreover, two patients, who failed CAR-T therapy and received REGN1979 80 mg, achieved complete responses.
The R/R follicular lymphoma (FL) grades 1 to 3a treatment arm showed an overall response rate of 93% (13 of 14 patients) in patients, who received doses of 5 mg or more, with a complete response rate of 71% (10 of 14 patients).
In DLBCL patients treated with REGN1979 80 mg to 160 mg, an overall response rate of 57% was observed.
In R/R DLBCL patients, whose disease progressed after CD-19 directed CAR-T therapy, 2 of 4 achieved a complete response.
As of the March 2019 data cutoff, safety was evaluated in 81 patients. The most common treatment-emergent adverse events (AEs) were pyrexia (83%), cytokine release syndrome (CRS; 57%), chills (54%), infections and infestations (49%), increased C-reactive protein (38%), fatigue (38%), anemia (36%) and thrombocytopenia (30%). Six patients experienced Grade 3 or higher CRS (7%).
The company will initiate a phase II program later in the month for a potential registration, and proactively evaluate active REGN1979 doses in indolent and aggressive non-Hodgkin lymphoma.
We remind investors that REGN1979 was granted Orphan Drug designation by the FDA for the treatment of DLBCL in 2017.
Regeneron currently has four different bispecific antibodies in clinical trials for both solid tumors and blood cancers. Among these, the first costimulatory bispecific antibody is REGN5678, which will be investigated in combination with Libtayo for prostate cancer.
The company is developing REGN1979 and REGN5678 for B-NHL and prostate cancer, respectively.
We note that Libtayo is being developed in collaboration with Sanofi (NASDAQ:SNY) .
Regeneron’s stock has lost 17.3% in the past six months compared with the Zacks Investment Research
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.